隨著國內外環境的快速變遷,市場競爭激烈、科技發展日新月異,許多廠商基於自身的資源有限及能力的不足,期望以外部成長的方式,採取「策略聯盟」的方法結合各怖少的有限資源、共同分攤研發的成本與風險,減少市場競爭,以增強自身的競爭優勢。此種情況尤其常見於高科技產業。雖然有許多文獻討論了可能造成策略聯盟的原因及其優缺點,但少有文獻具體地的以實證分析來證明其原因,更遑論台灣的實證分析。於是,本研究針對一新興高科技產業一生物技術產業一做一分析,以期了解何種形式的廠商適合有策略聯盟,並進一步討論假設與美國的實證結果均屬一致,主要發現為三:策略聯盟較容易發生在小型、且著重研發的廠商:研發性策略聯盟發生在非股票上市上櫃廠商較股票上市上櫃廠商較多:廠商之策略聯盟數量隨著廠商年齡的增加而逐漸減少。至於台灣的實證部分,分析結果僅部分與理論相符。
In response to the rapidly changing environment and technology around the world and the more competitive market situation, many firms form strategic alliances possibly due to their incomplete ability or limited resources. By allying with others, firms may share costs and risks, and may lower competitiveness within the industry. This tactic is more observed in to higher-tech industries. Much existing literature has discussed the causes, pros, and cons of alliances, but few have theoretically or empirically proven them. This paper takes one rising high-tech industry--biotechnology--as an example and tries to empirically test the reasons behind strategic alliances and analyzes what kind of firms are likely to form them. Theoretical assumptions are first made and followed by empirical analyses. The sample includes both Taiwan and US biotech firms. Firms from different countries are analyzed separately and then results from each country are compared and contrasted. The results from the US firms are in general consistent with the theoretical predictions: strategic alliances are more likely to happen in small, research oriented firms; research type alliances are more likely to occur in none-publicly traded firms; and, the intense use of alliances decreases as the ages of the firms increase. Only part of the Taiwan results are consistent with the theoretical predications.